Difference between revisions of "Retaspimycin (IPI-504)"
Jump to navigation
Jump to search
(Created page with "'''In clinical trials.''' Also known as IPI504, Retaspimycin HCl. ==General information== Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaper...") |
Warner-admin (talk | contribs) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, retaspimycin may accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.<ref>[http://www.infi.com/product-candidates-pipeline-ipi-504.asp Retaspimycin (IPI-504) manufacturer's website]</ref><ref>[http://www.gistsupport.org/treatments-for-gist/emerging-treatments/hsp90-inhibitors/ipi-504-retaspimycin.php GIST Support International (GSI) page about Retaspimycin (IPI-504)]</ref> | Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, retaspimycin may accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.<ref>[http://www.infi.com/product-candidates-pipeline-ipi-504.asp Retaspimycin (IPI-504) manufacturer's website]</ref><ref>[http://www.gistsupport.org/treatments-for-gist/emerging-treatments/hsp90-inhibitors/ipi-504-retaspimycin.php GIST Support International (GSI) page about Retaspimycin (IPI-504)]</ref> | ||
| Line 7: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
No information available. | No information available. | ||
| + | |||
| + | ==Also known as== | ||
| + | IPI504, Retaspimycin HCl | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Intravenous chemotherapy]] | ||
| + | |||
| + | [[Category:Hsp90 inhibitors]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 03:01, 25 July 2017
General information
Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, retaspimycin may accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Also known as
IPI504, Retaspimycin HCl